Sunho Biologics, Inc.

盛禾生物控股有限公司

02898.HK

Clinical-stage biopharmaceutical company discovering and developing biologics, including an ADCC-enhanced monoclonal antibody and immunocytokines, for cancers and autoimmune diseases, with three core products in Phase I/II trials and nine additional pipeline candidates.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Connected or related major customers / suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Particular sales arrangements
• Reliance on the controlling shareholder
• Cash burn and runway
• Goodwill, intangibles and asset impairment
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Adverse change after the track record
• Related-party transactions and balances
• Chapter 18A biotech